Refreshed content for TB-500 (Thymosin Beta-4)ai_activityai-researcherApr 17, 2026
Pulled 3 linked studies for context.
No external link
Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).
Community effect votes, structured logs, and side-effect summaries.
Effect profile (overview)
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
Pain / discomfort-1/5
Sleep / recovery0/5
Performance / output+4/5
Based on 4 anonymized research logs. Scroll down for full context and methodology.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
Last analyzed Apr 17, 20263
Studies indexed
0
Human
0
Animal
0
AI analyzed
Evidence mix0% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: —
Librarian pulse — latest actionsFull changelog ↓
- Apr 17, 12:04 PMRefreshedRefreshed content for TB-500 (Thymosin Beta-4)
- Apr 16, 5:13 PMRefreshedRefreshed content for TB-500 (Thymosin Beta-4)
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
Refreshed content for TB-500 (Thymosin Beta-4)ai_activityai-researcherApr 16, 2026
Pulled 3 linked studies for context. - **content** added: Body content generated (1195 chars).
No external link
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular BiomarkersClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the safety, tolerability, pharmacokinetics, and exploratory cardiovascular biomarkers of TB-500 (Thymosin Beta 4 17-23 Fragment) in adults with stable atherosclerotic cardiovascular disease. The study was designed as a Phase 1/2, randomized, double-blind, placebo-controlled trial. Specific outcomes and numeric findings are not reported in the abstract.
Phase: PHASE1, PHASE2Status: RECRUITING
Semantic Scholar search for TB-500 (Thymosin Beta-4)StudySemanticScholarDec 12, 2025
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.StudyPubMedDec 12, 2025
Drug testing and analysis · 2012
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.StudyPubMedDec 12, 2025
Journal of chromatography. A · 2012
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
Showing the latest 4 logs out of 4.
Goal: injury / tissue repair
Context: unspecified training level • age not given
Duration not specified
Δ scores
Pain +0Sleep +3Perf +5
Goal: injury / tissue repair
Context: unspecified training level • age not given
Duration not specified
Δ scores
Pain -5Sleep +0Perf +5
Goal: injury / tissue repair
Context: unspecified training level • age not given
Duration not specified
Δ scores
Pain +0Sleep -4Perf +5
Goal: injury / tissue repair
Context: unspecified training level • age not given
Duration not specified
Δ scores
Pain +0Sleep +0Perf +0
How to read these logs
Each entry is a single, anonymized “n=1” summary with relative change sliders from −5 to +5. Higher positive values indicate perceived improvement; negative values indicate perceived worsening.
Context (training level, age band, duration, and dosing frequency) is shown so you can quickly skim for patterns or outliers. Treat this as qualitative signal layered on top of study data, not as a substitute for controlled trials.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Librarian Changelog
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
22h agoRefreshai-researcher85%
Refreshed content for TB-500 (Thymosin Beta-4)
1d agoRefreshai-researcher85%
Refreshed content for TB-500 (Thymosin Beta-4)